{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:21:11Z","timestamp":1760984471488},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1986,7]]},"DOI":"10.1212\/wnl.36.7.932","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T12:40:06Z","timestamp":1336912806000},"page":"932-932","update-policy":"http:\/\/dx.doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Neuropathologic verification of Creutzfeldt\u2010Jakob disease in the exhumed American recipient of human pituitary growth hormone"],"prefix":"10.1212","volume":"36","author":[{"given":"Ron","family":"Tintner","sequence":"first","affiliation":[{"name":"Department of Neurology (Dr. Tintner), The University of Texas Health Science Center, Dallas, TX; Laboratory of CNS Studies (Drs. Brown, Piccardo, and Gajdusek), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; Laboratory for Neuropathology (Dr. Hedley-Whyte), Massachusetts General Hospital, Boston, MA; and the Division of Metabolism and Endocrine Drug Products (Dr. Rappaport), Food and Drug Administration, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Neurology (Dr. Tintner), The University of Texas Health Science Center, Dallas, TX; Laboratory of CNS Studies (Drs. Brown, Piccardo, and Gajdusek), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; Laboratory for Neuropathology (Dr. Hedley-Whyte), Massachusetts General Hospital, Boston, MA; and the Division of Metabolism and Endocrine Drug Products (Dr. Rappaport), Food and Drug Administration, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Tessa","family":"Hedley-Whyte","sequence":"additional","affiliation":[{"name":"Department of Neurology (Dr. Tintner), The University of Texas Health Science Center, Dallas, TX; Laboratory of CNS Studies (Drs. Brown, Piccardo, and Gajdusek), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; Laboratory for Neuropathology (Dr. Hedley-Whyte), Massachusetts General Hospital, Boston, MA; and the Division of Metabolism and Endocrine Drug Products (Dr. Rappaport), Food and Drug Administration, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Rappaport","sequence":"additional","affiliation":[{"name":"Department of Neurology (Dr. Tintner), The University of Texas Health Science Center, Dallas, TX; Laboratory of CNS Studies (Drs. Brown, Piccardo, and Gajdusek), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; Laboratory for Neuropathology (Dr. Hedley-Whyte), Massachusetts General Hospital, Boston, MA; and the Division of Metabolism and Endocrine Drug Products (Dr. Rappaport), Food and Drug Administration, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Pedro","family":"Piccardo","sequence":"additional","affiliation":[{"name":"Department of Neurology (Dr. Tintner), The University of Texas Health Science Center, Dallas, TX; Laboratory of CNS Studies (Drs. Brown, Piccardo, and Gajdusek), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; Laboratory for Neuropathology (Dr. Hedley-Whyte), Massachusetts General Hospital, Boston, MA; and the Division of Metabolism and Endocrine Drug Products (Dr. Rappaport), Food and Drug Administration, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Carleton","family":"Gajdusek","sequence":"additional","affiliation":[{"name":"Department of Neurology (Dr. Tintner), The University of Texas Health Science Center, Dallas, TX; Laboratory of CNS Studies (Drs. Brown, Piccardo, and Gajdusek), National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; Laboratory for Neuropathology (Dr. Hedley-Whyte), Massachusetts General Hospital, Boston, MA; and the Division of Metabolism and Endocrine Drug Products (Dr. Rappaport), Food and Drug Administration, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.36.7.932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T18:09:12Z","timestamp":1711649352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.36.7.932"}},"subtitle":["Epidemiologic and pathogenetic implications"],"short-title":[],"issued":{"date-parts":[[1986,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1986,7]]}},"alternative-id":["10.1212\/WNL.36.7.932"],"URL":"https:\/\/doi.org\/10.1212\/wnl.36.7.932","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,7]]}}}